(R)-warfarin

DB08496

small molecule experimental

Deskripsi

Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways. S-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.A1038

Struktur Molekul 2D

Berat 308.3279
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi The volume of distribution was 10.9L (95% confidence interval 8.63, 13.2), according to a study by Lane et al. [A7166]
Klirens (Clearance) 0.125L/h, (95% confidence interval 0.115, 0.135) in a 70kg individual aged 69.8yr with the wild type CYP2C19 and CYP3A4 genotypes.

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

5 Data
  • 1. Avoid drastic dietary changes.
  • 2. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
  • 3. Ensure consistent Vitamin K intake.
  • 4. Exercise caution with grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum levels of R-warfarin.
  • 5. Exercise caution with St. John's Wort. This herb induces CYP3A4 metabolism, which may reduce the serum levels of R-warfarin.

Interaksi Obat

1758 Data
Apixaban Apixaban may increase the anticoagulant activities of (R)-warfarin.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of (R)-warfarin.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with (R)-warfarin.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when (R)-warfarin is combined with Deferasirox.
Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Cholic Acid.
Glycocholic acid The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Taurocholic acid.
Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Hyodeoxycholic Acid.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with (R)-warfarin.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with (R)-warfarin.
Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when (R)-warfarin is combined with Obinutuzumab.
Rivaroxaban (R)-warfarin may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when (R)-warfarin is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of (R)-warfarin.
Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with (R)-warfarin.
Urokinase Urokinase may increase the anticoagulant activities of (R)-warfarin.
Vitamin E Vitamin E may increase the anticoagulant activities of (R)-warfarin.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with (R)-warfarin.
Peginterferon alfa-2b The serum concentration of (R)-warfarin can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of (R)-warfarin can be decreased when it is combined with Leflunomide.
Dabrafenib The serum concentration of (R)-warfarin can be decreased when it is combined with Dabrafenib.
Luliconazole The serum concentration of (R)-warfarin can be increased when it is combined with Luliconazole.
Mirtazapine Mirtazapine may increase the anticoagulant activities of (R)-warfarin.
Sorafenib The risk or severity of bleeding can be increased when Sorafenib is combined with (R)-warfarin.
Mifepristone The serum concentration of (R)-warfarin can be increased when it is combined with Mifepristone.
Gemcitabine The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Gemcitabine.
Trilostane Trilostane may increase the anticoagulant activities of (R)-warfarin.
Ciclesonide Ciclesonide may increase the anticoagulant activities of (R)-warfarin.
Aldosterone Aldosterone may increase the anticoagulant activities of (R)-warfarin.
Fluprednidene Fluprednidene may increase the anticoagulant activities of (R)-warfarin.
Tixocortol Tixocortol may increase the anticoagulant activities of (R)-warfarin.
Fluprednisolone Fluprednisolone may increase the anticoagulant activities of (R)-warfarin.
Meprednisone Meprednisone may increase the anticoagulant activities of (R)-warfarin.
Melengestrol Melengestrol may increase the anticoagulant activities of (R)-warfarin.
Deflazacort Deflazacort may increase the anticoagulant activities of (R)-warfarin.
Cortivazol Cortivazol may increase the anticoagulant activities of (R)-warfarin.
Prednylidene Prednylidene may increase the anticoagulant activities of (R)-warfarin.
Fluocortin Fluocortin may increase the anticoagulant activities of (R)-warfarin.
Fluperolone Fluperolone may increase the anticoagulant activities of (R)-warfarin.
Cloprednol Cloprednol may increase the anticoagulant activities of (R)-warfarin.
Fluclorolone Fluclorolone may increase the anticoagulant activities of (R)-warfarin.
Mometasone furoate Mometasone furoate may increase the anticoagulant activities of (R)-warfarin.
Hydrocortisone cypionate Hydrocortisone cypionate may increase the anticoagulant activities of (R)-warfarin.
Prednisolone phosphate Prednisolone phosphate may increase the anticoagulant activities of (R)-warfarin.
Prednisolone hemisuccinate Prednisolone hemisuccinate may increase the anticoagulant activities of (R)-warfarin.
Methylprednisolone hemisuccinate Methylprednisolone hemisuccinate may increase the anticoagulant activities of (R)-warfarin.
Prednisone acetate Prednisone acetate may increase the anticoagulant activities of (R)-warfarin.
Clocortolone acetate Clocortolone acetate may increase the anticoagulant activities of (R)-warfarin.
Melengestrol acetate Melengestrol acetate may increase the anticoagulant activities of (R)-warfarin.
Betamethasone phosphate Betamethasone phosphate may increase the anticoagulant activities of (R)-warfarin.
Cortisone Cortisone may increase the anticoagulant activities of (R)-warfarin.
Paramethasone Paramethasone may increase the anticoagulant activities of (R)-warfarin.
Fluticasone furoate Fluticasone furoate may increase the anticoagulant activities of (R)-warfarin.
Fluticasone Fluticasone may increase the anticoagulant activities of (R)-warfarin.
Fludrocortisone Fludrocortisone may increase the anticoagulant activities of (R)-warfarin.
Prednisone Prednisone may increase the anticoagulant activities of (R)-warfarin.
Clobetasol propionate Clobetasol propionate may increase the anticoagulant activities of (R)-warfarin.
Fluocinonide Fluocinonide may increase the anticoagulant activities of (R)-warfarin.
Hydrocortisone butyrate Hydrocortisone butyrate may increase the anticoagulant activities of (R)-warfarin.
Desoximetasone Desoximetasone may increase the anticoagulant activities of (R)-warfarin.
Mometasone Mometasone may increase the anticoagulant activities of (R)-warfarin.
Fluocortolone Fluocortolone may increase the anticoagulant activities of (R)-warfarin.
Prednisolone acetate Prednisolone acetate may increase the anticoagulant activities of (R)-warfarin.
Fluorometholone Fluorometholone may increase the anticoagulant activities of (R)-warfarin.
Difluocortolone Difluocortolone may increase the anticoagulant activities of (R)-warfarin.
Flumethasone Flumethasone may increase the anticoagulant activities of (R)-warfarin.
Methylprednisolone aceponate Methylprednisolone aceponate may increase the anticoagulant activities of (R)-warfarin.
Ritonavir The serum concentration of (R)-warfarin can be decreased when it is combined with Ritonavir.
Erlotinib The serum concentration of (R)-warfarin can be increased when it is combined with Erlotinib.
Tigecycline The serum concentration of (R)-warfarin can be increased when it is combined with Tigecycline.
Imatinib Imatinib may increase the anticoagulant activities of (R)-warfarin.
Trazodone Trazodone may decrease the anticoagulant activities of (R)-warfarin.
Allopurinol The risk or severity of bleeding can be increased when Allopurinol is combined with (R)-warfarin.
Viloxazine The metabolism of (R)-warfarin can be decreased when combined with Viloxazine.
Methylene blue The serum concentration of (R)-warfarin can be increased when it is combined with Methylene blue.
Azelastine The metabolism of (R)-warfarin can be decreased when combined with Azelastine.
Aldesleukin The serum concentration of (R)-warfarin can be increased when it is combined with Aldesleukin.
Octreotide The serum concentration of (R)-warfarin can be increased when it is combined with Octreotide.
Fluvoxamine The serum concentration of (R)-warfarin can be increased when it is combined with Fluvoxamine.
Fluconazole The serum concentration of (R)-warfarin can be increased when it is combined with Fluconazole.
Citalopram The risk or severity of bleeding can be increased when (R)-warfarin is combined with Citalopram.
Lovastatin The risk or severity of bleeding can be increased when Lovastatin is combined with (R)-warfarin.
Ziprasidone The serum concentration of (R)-warfarin can be increased when it is combined with Ziprasidone.
Cabergoline The serum concentration of (R)-warfarin can be increased when it is combined with Cabergoline.
Diethylstilbestrol The serum concentration of (R)-warfarin can be increased when it is combined with Diethylstilbestrol.
Isradipine The serum concentration of (R)-warfarin can be increased when it is combined with Isradipine.
Valproic acid The serum concentration of (R)-warfarin can be increased when it is combined with Valproic acid.
Dihydroergotamine The serum concentration of (R)-warfarin can be increased when it is combined with Dihydroergotamine.
Diltiazem The serum concentration of (R)-warfarin can be increased when it is combined with Diltiazem.
Methylergometrine The serum concentration of (R)-warfarin can be increased when it is combined with Methylergometrine.
Mefloquine The serum concentration of (R)-warfarin can be increased when it is combined with Mefloquine.
Nitric Oxide The serum concentration of (R)-warfarin can be increased when it is combined with Nitric Oxide.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 21692828
    Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, Deloukas P, Daly AK, Park BK, Aarons L, Ogungbenro K, Kamali F, Hughes D, Pirmohamed M: The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol. 2012 Jan;73(1):66-76. doi: 10.1111/j.1365-2125.2011.04051.x.
  • PMID: 11673021
    Ragueneau-Majlessi I, Levy RH, Meyerhoff C: Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 2001 Nov;47(1-2):55-63.
  • PMID: 12742309
    Hirsh J, Fuster V, Ansell J, Halperin JL: American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003 May 7;41(9):1633-52.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul